with colonic involvement, patients with a personal history of venous thromboembolism that will undergo surgery, patients with a family history of venous thromboembolism in a first-degree relative, known thrombophilia, persistent antiphospholipid antibodies, oral contraceptive use, thalidomide use, smoking, obesity, or a central venous catheter.9

Low-molecular-weight heparin is recommended in children as follows: in those that weigh less than 60 kg, 0.5 mg/kg twice a day, subcutaneously, and in those that weigh more than 60 kg, subcutaneous administration of 30 mg twice a day or 40 mg once a day.3

Thrombotic status should be monitored, and risk factors identified, as an integral part of IBD treatment.

Ethical considerations

The authors declare that the present article contains no personal information enabling the identification of the patient, who remains completely anonymous. Because the article is based on the review of a case record, no authorization by the hospital ethics committee was required.

Financial disclosure

No specific grants were received from public sector agencies, the business sector, or non-profit organizations in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.

Acknowledgements

The authors wish to thank Dr. Judmila López Sánchez at the Department of Neurology of the Hospital Infantil de México Federico Gómez, SSA, Mexico City, Mexico.

References


Y. Rivera-Suazo, I. Argüello Calderon, R. Vázquez-Frias*
Departamento de Gastroenterología y Nutrición, Hospital Infantil de México Federico Gómez, SSA, Mexico City, Mexico
*Corresponding author at: Dr. Márquez 162, Doctores, Cuauhtémoc, Benito Juárez, Mexico. Tel.: 52289917, extensión 2139.
E-mail address: rovaf@yahoo.com (R. Vázquez-Frias).

2255-534X/ © 2019 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Strongyloides infection mimicking inflammatory bowel disease

Infección por Strongyloides imitando enfermedad inflamatoria intestinal

Strongyloidiasis is an endemic disease in tropical and subtropical regions. It is reported more frequently in immunosuppressed patients and presents with abdominal pain, diarrhea, constipation, nausea and/or anorexia.1 It usually compromises the duodenum and is rare in the colon. Its prevalence varies, reaching 25% in some areas, and is estimated at 2.7% in Peru. It affects up to 40% of the population in the Peruvian Amazon.2

A 32-year-old woman presented with 3-week progression of abdominal pain, liquid stools with mucus but no blood, nausea, vomiting, and weight loss. Physical examination revealed white plaques in her oral cavity and a soft, depressible abdomen whose lower half was painful. Digital rectal examination showed no signs of bleeding. Laboratory test results were: hemoglobin 10.1 g/dl, leukocytes 7,900/µl, eosinophils 11.2% (880/µl), total proteins 5.2 g/dl, albumin 3 g/dl, fecal leukocytes 50–80/µl field, red blood cells: 0/µl field, negative parasitologic testing, and a positive ELISA HIV test. From the cecum to the prox-
Figure 1  a) Edematous colonic mucosa, with a nodular pattern, erythema, and ulcers. b) Sigmoid colon with flattened haustra, vascular pattern loss, edema, erythema, and erosions.

imal rectum, colonoscopy identified vascular pattern loss, shortening of the haustra, mucosal edema, erythema, some 3–4 mm ulcers covered with fibrin at the base, and segments with a nodular aspect (Fig. 1a and b). The histology study findings were 30–40 eosinophils per high power field, acute and chronic inflammatory infiltrate, mild distortion of the glandular architecture, and rhabditiform *Strongyloides stercoralis* larvae (Fig. 2). The evaluation was completed with upper gastrointestinal endoscopy, distinguishing erosions in the duodenum, pale areas, and absence of villi, with histologic evidence of *Strongyloides stercoralis* larvae.

The patient was treated with 200 μg/kg/day of ivermectin for 2 days, with favorable clinical progression, and a third dose 2 weeks later.

*Strongyloides stercoralis* has a complex life cycle, with the capacity to live and replicate in the host for decades because the rhabditiform larvae mature into filariform larvae in the gastrointestinal tract, penetrating the perianal skin or the colonic mucosa to complete the autoinfection cycle.

The risk factors for acquiring the infection are male sex, low socioeconomic status, alcoholism, white race, immunosuppression, and occupations in which there is contact with soil, such as agriculture and mining.

The clinical picture is composed of 4 aspects: a) acute strongyloidiasis, with local signs of skin irritation due to the entrance of the larvae, and bronchitis due to their migration to the lungs; b) chronic strongyloidiasis, which is asymptomatic in the majority of patients, but others can present with diarrhea, constipation, abdominal pain, nausea, or asthma; c) superinfection, characterized by a cycle of accelerated autoinfection that exacerbates the gastrointestinal and pulmonary symptoms and generally develops in immunocompromised patients; and d) dissemination, a form of superinfection that includes areas outside of the normal life cycle (gastrointestinal tract, peritoneum, and lungs), in which larvae can be found in the central nervous system, liver, kidney, and other organs.

The presentation of superinfection, with or without dissemination, is a potentially lethal form whose development is generally related to immunosuppression, corticotherapy, post-transplantation, hematologic neoplasia. It is often associated with HTLV-1 coinfection, conditioning failure in the Th-2 lymphocyte response in charge of controlling the infection of the parasite.

HIV has also been described as a risk factor for *Strongyloides stercoralis* infection. However, the Th-2 response is not reduced, explaining the lower risk for the disseminated disease. Our patient tested positive for HIV infection and negative for HTLV-1, developing symptomatic chronic strongyloidiasis associated with peripheral eosinophilia.

Colitis due to *Strongyloides* infection can resemble ulcerative colitis, but its distinctive characteristics are: attenuated lesion in the distal colon and rectum, lesions in patches (areas of normal mucosa), eosinophil-rich infiltrates, relatively intact crypt architecture, and frequent involvement of the submucosa. Colonoscopy can reveal mucosal edema, erosions, pseudopolyps, bleeding, and ulcerations, alternating with normal parts of the mucosa.

The differential diagnoses include inflammatory bowel disease (IBD), amoebiasis, colitis due to *Shigella, Campylobacter*, or *Yersinia*, drug-induced colitis, eosinophilic colitis, and ischemic colitis.

Treatment for chronic strongyloidiasis is 200 μg/kg/day oral ivermectin for 2 days, repeating the dose in 2 weeks. In severe cases, administration should be parenteral (subcutaneous) at a dose of 200 μg/kg/day for a varied period of time (3–22 doses). Treatment and follow-up are recommended to be continued until a fecal culture in an agar plate for *S. ster-
Lipomas
Soft
Incidence
de
declaring
statement
of
No
The
Lipoma
coralis
un
interesfíntrica
References
Ethical
considerations
The
present
scientific
letter
follows
the
guidelines
of
the
1975
Declaration
of
Helsinki.
No
authorization
by
an
ethics
committee
or
patient
informed
consent
for
receiving
a
treatment
was
required,
given
that
we
only
described
a
case,
respecting
the
case’s
privacy.
The
authors
declare
that
no
personal
information
of
the
patient
appears
in
the
letter
and
patient
anonymity
was
respected,
making
consent
for
publication
unnecessary.
Protection
of
human
and
animal
subjects.
The
authors
declare
that
no
experiments
were
performed
on
humans
or
animals
for
this
study.
Confidentiality
of
data.
The
authors
declare
that
the
patient
data
that
appear
in
this
article
are
completely
anonymous.
Right
to
privacy
and
informed
consent.
The
authors
declare
that
they
have
respected
the
privacy
of
the
patient
data
and
have
the
consent
for
publication
signed
by
the
authors.
Financial
disclosure
No
specific
grants
were
received
from
public
sector
agencies,
the
business
sector,
or
non-profit
organizations
in
relation
to
this
study.
Conflict
of
interest
The
authors
declare
that
there
is
no
conflict
of
interest.
References
1. Marcos
LA,
Terashima
A,
Canales
M,
et
al.
Update
on
strongyloidiasis
in
the
immunocompromised
host.
Curr
Infect
Dis
Rep.
2. Vildosola
Gonzales
H.
Estrangiloidiasis.
Rev
Gastroenterol
Perú.
1997;17
Supl1:S75–91.
3. Poveda
J,
Sharkawy
F,
Arosemena
LR,
et
al.
Strongyloides
colitis
as
a
harmful
mimicker
of
inflammatory
bowel
disease.
Case
Rep
Pathol.
2017;2017:2560719,
http://dx.doi.org/10.1155/2017/2560719.
4. Minematsu
H,
Hokama
A,
Makishi
T,
et
al.
Colonoscopic
findings
and
pathologic
characteristics
of
Strongyloides
colitis:
a
case
series.
Digestion.
5. Keiser
PB,
Nutman
TB.
Strongyloides
stercoralis
in
the
immuno-compromised
population.
Clin
Microbiol
Rev.
6. Grossi
PA,
Lombardi
D,
Petrolo
A,
et
al.
Strongyloides
stercoralis
hyperinfection
in
an
hiv-infected
patient
successfully
-treated
with
subcutaneous
ivermectin.
Trop
Med
Inf
Dis.
2018;3:46.
7. Siegel
M,
Simon
G.
Is
human
immunodeficiency
virus
infection
a
risk
factor
for
Strongyloides
stercoralis
hyperinfection
and
dissemination.
PloS
Negl
Trop
Dis.
2012;6:e1581.
8. Kishimoto
K,
Hokama
A,
Hirata
T,
et
al.
Endoscopic
and
histopathological
study
on
the
duodenum
of
Strongyloides
stercoralis
hyperinfection.
World
J
Gastroenterol.
2008;14:1768–73.
9. Qu
Z,
Kundu
UR,
Abadeer
RA,
et
al.
Strongyloides
colitis
is
a
lethal
mimic
of
ulcerative
colitis:
the
key
morphologic
differential
diagnosis.
Hum
Pathol.
10. Luwira
V,
Wathanakulpanich
D,
Pittisuttithum
P.
Management
of
Strongyloides
stercoralis:
A
puzzling
parasite.
Int.
Health.
P.
Gomez-Hinojosa
a,∗,1
C.
García-Encinas
b,
A.
Carlin-Ronquillo
a,
R.P.
Chancafe-Morgan
b,
J.
Espinoza-Ríos
a,c
a
Servicio
de
Gastroenterología,
Departamento
de
Medicina,
Hospital
Cayetano
Heredia,
Lima,
Peru
b
Servicio
de
Anatomía
Patológica,
Hospital
Cayetano
Heredia,
Lima,
Peru
∗
Universidad
Peruana
Cayetano
Heredia,
Lima,
Peru
∗∗
Corresponding
author:
Jr.
Alheli
# 874
- San
Martín
de
Porres,
Tel.: +984342744.
E-mail
address:
pagoh@hotmail.com
(P.
Gomez-Hinojosa).
2255-534X/©2019
Asociación
Méxicana
de
Gastroenterología.
Published
by
Masson
Doyma
México
S.A.
This
is
an
open
access
article
under
the
CC
BY-NC-ND
license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

Perianal
lipoma
with
an
intersphincteric
fistula
in
an
adult
patient

Lipoma
perianal
con
fistula
interesfíntrica
en
un
paciente
adulto

An
anal
fistula,
or
fistula-in-ano,
is
an
abnormal
granulat-
ing
tract
between
the
anorectum
and
the
perianal
region.
Incidence
varies
between
0.86
and
2.32
per
10,000/year
and
is
predominant
in
males,
with
ratios
ranging
from
2:1
to
5:1.1
Lipomas
are
benign
soft
tissue
tumors
composed
of
adipocytes
within
a
thin
fibrous
capsule
and
account
for
almost
50%
of
all
soft
tissue
tumors.2
Able
to
occur
in
any
part
of
the
body
that
has
normal
fat
deposits,
they
develop
where
those
deposits
are
greatest,
such
as
the
trunk,
fore-
arms,
and
thighs.
Lipomas
are
rarely
found
in
areas
that
naturally
have
little
fat,
such
as
the
perineum.5
Soft
tissue
lipomas
are
commonly
seen
in
daily
practice
and
present
in
around
2%
of
the
population.5
A
35-year-old
man
had
an
unremarkable
past
medical
history,
except
for
surgical
drainage
of
a
perianal
abscess,
7
years
prior.
He
arrived
at
our
surgical
clinic,
presenting
with
a
purulent
discharge
and
drainage
of
pus
near
the
anus
that
irritated
the
perianal
space
and
the
anal
canal,
causing
itching
and
discomfort.
He
stated
that
his
symptoms
had
not

Please
cite
this
article
as:
González-Urquijo
M,
Zambrano-Lara
M,
Espinosa-Loera
JJ,
Gil-Galindo
G.
Lipoma
perianal
con
fistula
interesfíntrica
en
un
paciente
adulto.
Revista
de
Gastroenterología
de
México.
2020.
https://doi.org/10.1016/j.rgmx.2019.08.007